{"ticker": {"uuid": "9647edfd-1498-4284-81ed-6e73df6e6f78", "symbol": "ANVS", "name": "Annovis Bio\u00a0Inc", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Annovis Reaches Full Enrollment in Phase 3 Buntanetap Trial, 850 Patients Enrolled", "summary": "Annovis Bio (ANVS) has fully enrolled 850 pTau217-confirmed early Alzheimer's disease patients in its pivotal Phase 3 buntanetap trial across 83 U.S. sites. The trial is randomized, placebo-controlled, and double-blind, with primary endpoints of ADAS-Cog13 and ADCS-iADL. Dual rea", "url": "https://www.tradingview.com/news/tradingview:b17ba2fb265f7:0-annovis-reaches-full-enrollment-in-phase-3-buntanetap-trial-850-patients-enrolled/", "source_name": "TradingView", "published_at": "2026-07-10T10:39:18", "published_display": "10 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio (NYSE: ANVS) completes enrollment in 850-patient Phase 3 Alzheimer\u2019s study", "summary": "Annovis Bio has announced the full enrollment of 850 patients in its pivotal Phase 3 trial for buntanetap, an investigational oral therapy for early Alzheimer's disease. The trial, exceeding original enrollment projections, will feature two separate data readouts: a 6-month sympt", "url": "https://www.stocktitan.net/sec-filings/ANVS/8-k-annovis-bio-inc-reports-material-event-00271f5e0b37.html", "source_name": "Stock Titan", "published_at": "2026-07-10T09:39:17", "published_display": "10 Jul 2026 09:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roth MKM Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $8", "summary": "Roth MKM has reiterated its Buy rating for Annovis Bio (ANVS.US) and maintained a target price of $8. This indicates the firm's continued confidence in the company's prospects.", "url": "https://www.moomoo.com/news/post/72737386/roth-mkm-maintains-annovis-bio-anvsus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-10T01:11:49", "published_display": "10 Jul 2026 01:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts\u2019 Top Healthcare Picks: Evolus (EOLS), Annovis Bio (ANVS)", "summary": "This article highlights two healthcare stocks, Evolus (EOLS) and Annovis Bio (ANVS), that analysts are bullish on. Evolus received a Buy rating and a $15.00 price target from Mizuho Securities, with a consensus of Strong Buy. Annovis Bio also maintained a Buy rating and an $8.00 ", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3211700/analysts-top-healthcare-picks-evolus-eols-annovis-bio-anvs/", "source_name": "The Globe and Mail", "published_at": "2026-07-09T20:14:16", "published_display": "09 Jul 2026 20:14", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Promotes Research Chief as Lead Drug Nears Key Trial", "summary": "Annovis Bio has promoted Cheng Fang to Chief Scientific Officer as the company advances its lead drug candidate, buntanetap, towards key clinical and regulatory milestones for Alzheimer's disease. Fang will oversee scientific strategy, clinical development, and regulatory interac", "url": "https://www.mychesco.com/a/news/business/executives/annovis-promotes-research-chief-as-lead-drug-nears-key-trial/", "source_name": "MyChesCo", "published_at": "2026-07-08T11:09:18", "published_display": "08 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The timeline for the key clinical trial data readout of Annovis Bio Inc. has been clarified.", "summary": "Annovis Bio Inc. has provided a clarified timeline for its key clinical trial data readouts. Results concerning symptom improvement efficacy are anticipated in the first quarter of 2027, while data evaluating the drug's impact on disease progression is expected in the first quart", "url": "https://www.bitget.com/amp/news/detail/12560605493681", "source_name": "Bitget", "published_at": "2026-07-07T13:11:18", "published_display": "07 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio completes enrollment in phase 3 Alzheimer\u2019s trial By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQZjlSdUtFbERrQWRhMno3R0l2alctWmFXN2NrbHBHU1ZZNDF4N2VNaFdOWGh6cEw5ZHlERy0tQncwbHJ0SGZ3X1h0Y19kelQ4UEpBU3dyZ0N5TVdYeWtIcy1UdTRLWmxtbTQ4XzMxd3lVaGYwcXZxWFJVdWc5T3RTNUF0ODI2VVRmTk5uV255anJYUWdkUFNlVlRzMUd4NEhfZkJOVGNUSnZ3amtGT3JZZGpSaGRva2hEdUdyRUVn?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T12:01:44+00:00", "published_display": "07 Jul 2026 12:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio Completes Patient Enrollment for Phase 3 Study of Buntanetap in Alzheimer's Disease", "summary": "Annovis Bio has successfully completed patient enrollment for its Phase 3 clinical trial evaluating buntanetap in patients with early Alzheimer's disease. The trial has fully enrolled 325 subjects across 50 sites, with topline results anticipated in the first quarter of 2027. Thi", "url": "https://www.moomoo.com/news/post/72582865/annovis-bio-completes-patient-enrollment-for-phase-3-study-of", "source_name": "Moomoo", "published_at": "2026-07-07T12:10:18", "published_display": "07 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio completes enrollment in phase 3 Alzheimer\u2019s trial", "summary": "Annovis Bio Inc. has successfully completed the enrollment of 850 patients in its pivotal Phase 3 clinical trial for buntanetap, a treatment for early Alzheimer\u2019s disease. The trial, exceeding its original enrollment target, will have two key data readouts: a 6-month analysis of ", "url": "https://www.investing.com/news/company-news/annovis-bio-completes-enrollment-in-phase-3-alzheimers-trial-93CH-4778792", "source_name": "Investing.com", "published_at": "2026-07-07T11:08:29", "published_display": "07 Jul 2026 11:08", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer\u2019s Disease", "summary": "Annovis Bio Inc. has fully enrolled its pivotal Phase 3 trial for buntanetap, an investigational oral therapy for early Alzheimer\u2019s disease, with 850 patients participating across 83 sites in the US. The trial aims to evaluate both symptomatic and disease-modifying effects, with ", "url": "https://www.globenewswire.com/news-release/2026/07/07/3323032/0/en/annovis-reaches-full-enrollment-in-pivotal-phase-3-trial-of-buntanetap-for-early-alzheimer-s-disease.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T11:00:03", "published_display": "07 Jul 2026 11:00", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis enrolls 850 patients in Phase 3 Alzheimer\u2019s study", "summary": "Annovis Bio (NYSE: ANVS) has fully enrolled 850 pTau217-positive patients in its pivotal Phase 3 trial of oral buntanetap for early Alzheimer\u2019s disease across 83 US sites. The dual-design study aims for 6-month symptomatic data by Q1 2027 and 18-month disease-modifying data by Q1", "url": "https://www.stocktitan.net/news/ANVS/annovis-reaches-full-enrollment-in-pivotal-phase-3-trial-of-g2h9kf5srbln.html", "source_name": "Stock Titan", "published_at": "2026-07-07T11:00:03", "published_display": "07 Jul 2026 11:00", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio Enrolls Over 850 Patients for Its Next Alzheimer's Disease Trial", "summary": "Annovis Bio announced the enrollment of over 850 patients for its upcoming Alzheimer's Disease trial. Sarah MacCallum and Cheng Fang from Annovis Bio discussed this development with Ashley Mastronardi on NYSE Live.", "url": "https://finance.yahoo.com/video/annovis-bio-enrolls-over-850-145156212.html", "source_name": "Market source", "published_at": "2026-07-07T10:51:00", "published_display": "07 Jul 2026 10:51", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The buntanetap program - Annovis Bio bets on neurodegeneration trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQdzU0bjRaUG5kdHc3V1Y2MDRLdFBES0Y5WXFDUmc1Uy1heWRUaGZ5eENTd2hKSFM0anBEN2dQY3RtRGZDTFdMRmMxWkROclc2VEpYdUxDa05KYUtDb25RYVpRcTBoWXhzUHZHMGtrb2d1WkpjZEpUU0JXaHhmUVZmckRGcU9qVXF1M1EyckI1ZWRaSHVwc1BZaGlDdW14ZUNsX0hDN1pkM2doODM1RnBZUXJpN0ZoOEw0ODl4dGhIekxOQnhS?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-04T22:38:45+00:00", "published_display": "04 Jul 2026 22:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer", "summary": "Annovis Bio, Inc. has promoted Dr. Cheng Fang to Chief Scientific Officer. Dr. Fang will lead the company's scientific strategy and research operations for its Alzheimer's and Parkinson's disease programs. Her promotion is critical as Annovis advances its lead drug candidate, bun", "url": "https://www.globenewswire.com/news-release/2026/07/01/3320540/0/en/annovis-appoints-cheng-fang-ph-d-as-chief-scientific-officer.html", "source_name": "GlobeNewswire", "published_at": "2026-07-01T21:09:44", "published_display": "01 Jul 2026 21:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio promotes Cheng Fang to chief scientific officer", "summary": "Annovis Bio Inc. has promoted Cheng Fang to Chief Scientific Officer. Fang will oversee the scientific strategy and research operations for the company's Alzheimer's and Parkinson's disease programs. This promotion comes as Annovis Bio advances its investigational oral therapy, b", "url": "https://www.investing.com/news/company-news/annovis-bio-promotes-cheng-fang-to-chief-scientific-officer-93CH-4770355", "source_name": "Investing.com", "published_at": "2026-07-01T12:41:06", "published_display": "01 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 62, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio Promotes Cheng Fang to Chief Scientific Officer Ahead of Phase 3 Milestones", "summary": "Annovis Bio Inc. has promoted Dr. Cheng Fang to Chief Scientific Officer, recognizing her expanded leadership role as the company approaches critical Phase 3 milestones for its lead drug candidate, buntanetap. Dr. Fang will now oversee scientific strategy and research operations ", "url": "https://www.citybiz.co/article/868362/annovis-bio-promotes-cheng-fang-to-chief-scientific-officer-ahead-of-phase-3-milestones/", "source_name": "citybiz", "published_at": "2026-07-01T12:40:18", "published_display": "01 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis elevates its R&D chief as Phase 3 Alzheimer\u2019s data nears", "summary": "Annovis Bio, Inc. has promoted Cheng Fang, Ph.D., to Chief Scientific Officer to lead scientific strategy and research operations for its Alzheimer\u2019s and Parkinson\u2019s programs. This promotion comes as the company approaches key milestones, including the release of top-line data fr", "url": "https://www.stocktitan.net/news/ANVS/annovis-appoints-cheng-fang-ph-d-as-chief-scientific-99hqqjrnidv9.html", "source_name": "Stock Titan", "published_at": "2026-07-01T11:40:18", "published_display": "01 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANVS - Annovis Bio Inc Latest SEC Filings", "summary": "This article provides detailed financial data and performance metrics for Annovis Bio Inc (ANVS), including its latest stock close, market capitalization, income, sales, and various valuation ratios. It also highlights insider and institutional ownership, short interest, and key ", "url": "https://finviz.com/stock?t=ANVS&ta=1&p=d&ty=lf&r=m1&page=6", "source_name": "Finviz", "published_at": "2026-06-30T20:40:18", "published_display": "30 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio, Inc.(NYSE: ANVS) added to Russell Microcap Index", "summary": "Annovis Bio, Inc. (NYSE: ANVS) has been added to the Russell Microcap Index. The company is a late-stage clinical drug platform company focused on neurodegenerative diseases like Alzheimer's and Parkinson's, developing product candidates such as Buntanetap, ANVS405, and ANVS301. ", "url": "https://www.marketscreener.com/news/annovis-bio-inc-nyse-anvs-added-to-russell-microcap-index-ce7f5fdeda80f02d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:40:27", "published_display": "29 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio, Inc.(NYSE: ANVS) added to Russell 3000E Index", "summary": "Annovis Bio, Inc. (NYSE: ANVS), a biotechnology company focused on neurodegenerative diseases, has been added to both the Russell 3000E Index and the Russell Microcap Index. This inclusion is a significant milestone, potentially increasing the company's visibility and attracting ", "url": "https://www.marketscreener.com/news/annovis-bio-inc-nyse-anvs-added-to-russell-3000e-index-ce7f5fdedd81f62c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T02:43:00", "published_display": "29 Jun 2026 02:43", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio, Inc.(NYSE: ANVS) added to Russell Microcap Growth Benchmark Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPSnNuSEp6YWdQWVI4XzdKUUVYTllpcVdsNUF0Nl9kUTBFeW1sY2pIUWtCWUZkZTIzTER3dkhXNng4UlkyM3gyeDN3RFZGMF8xOWxYZDlMMkRWNWZHMGdxUWZ4THpINklqWU1nS0UzSU9jRzRTYlpnVFp5eW1MM1RpWHdiT3RSd2s1M1drMVNQUm1aQVJYMHRHZHFtRTNNUUk5MWh2LUs4SWNwaW9zaEU1VlJudmRsUnVpY2lXcS15M0hsNnEzLWc?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T22:00:00+00:00", "published_display": "28 Jun 2026 22:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio Inc Actuals & Estimates (TRADEGATE:07X)", "summary": "This article provides an overview of Annovis Bio Inc (TRADEGATE:07X) financials and analyst estimates. It details the company's past earnings and revenue, future earnings forecasts, and historical stock performance including its all-time high and low prices. The article also conf", "url": "https://www.tradingview.com/symbols/TRADEGATE-07X/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T08:41:06", "published_display": "27 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio | DEFA14A: Others", "summary": "This article is a DEFA14A filing by Annovis Bio. DEFA14A filings are definitive additional soliciting materials filed with the SEC. The content of this specific filing is \"Document\".", "url": "https://www.moomoo.com/news/notice/307206668/annovis-bio-defa14a-others", "source_name": "Moomoo", "published_at": "2026-06-27T07:10:44", "published_display": "27 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio Inc Actuals & Estimates (FWB:07X)", "summary": "This article provides financial actuals and estimates for Annovis Bio Inc (FWB:07X), including analyst price targets, historical stock prices, and upcoming earnings dates. It highlights that the company's stock ticker on the FWB exchange is 07X and details past earnings performan", "url": "https://www.tradingview.com/symbols/FWB-07X/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:16", "published_display": "26 Jun 2026 07:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Annovis Bio, Inc. \u2013 NYSE:ANVS", "summary": "The document displays financial information for Annovis Bio, Inc. (NYSE: ANVS), specifically focusing on its forward price-to-sales ratio. It indicates that the market was closed with no trades at the time of viewing. The content primarily comes from TradingView, with market and ", "url": "https://www.tradingview.com/symbols/NYSE-ANVS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T06:11:23", "published_display": "26 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Annovis Bio, Inc. \u2013 NYSE:ANVS", "summary": "This article provides financial information for Annovis Bio, Inc. (NYSE:ANVS), specifically focusing on its enterprise value to revenue forward ratio. The content is primarily a data point or financial metric display from TradingView, which indicates the company's valuation relat", "url": "https://www.tradingview.com/symbols/NYSE-ANVS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T15:41:59", "published_display": "25 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio Inc (ANVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Annovis Bio Inc (ANVS), detailing its support, resistance, indicators, and moving averages. According to the analysis, various indicators like MACD and TRIX show sell signals, along with all moving averages from MA5 to MA200. The over", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anvs/technical", "source_name": "TradingKey", "published_at": "2026-06-21T17:10:34", "published_display": "21 Jun 2026 17:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio Shareholders Approve Governance and Compensation Changes", "summary": "Annovis Bio shareholders approved significant governance and compensation changes at their 2026 Annual Meeting, including the election of all five director nominees and the ratification of Ernst & Young LLP as auditor. Investors also approved an amendment to the 2019 Equity Incen", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ANVS-N/pressreleases/2547111/annovis-bio-shareholders-approve-governance-and-compensation-changes/", "source_name": "The Globe and Mail", "published_at": "2026-06-19T15:38:46", "published_display": "19 Jun 2026 15:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Annovis\u2019 buntanetap pill is drawing fresh attention in Alzheimer\u2019s race", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQcHVzUm5CWjVrYWNWSjY5a19FWV9qLUUwMjN6N2VuOEJ5bXNsUXpCTnJlQkZlTm9OS0M5a2M5NUJkaHFuYnljS1hkWTJ3MW5ZcXo4aXpMdmpKa2ptYm5SajRta2thWDE2a013Vk5oX3ptbHBONW5vX2V0b2VPMUthS2hoalg4elNoZHBIVEZCRUd5RzN5NGtRbDVfOEVaZWotV0ZqSVhxWF9CS3BRVnc2VVVrclBvdk51VUZuRUhOT25Ca29YdjIw?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio shareholders approve all proposals at annual meeting", "summary": "Annovis Bio, Inc. shareholders approved all proposals at their 2026 Annual Meeting. Key approvals included the re-election of five directors, the ratification of Ernst & Young LLP as auditors, and an amendment to the 2019 Equity Incentive Plan to increase issuable shares. Shareho", "url": "https://m.investing.com/news/sec-filings/annovis-bio-shareholders-approve-all-proposals-at-annual-meeting-93CH-4748658?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-17T22:39:52", "published_display": "17 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio Inc (ANVS) Institutional Confidence", "summary": "This article from TradingKey provides an overview of Annovis Bio Inc (ANVS) with a specific focus on \"Institutional Confidence.\" It lists key institutional shareholders and their recent activity, including shares held and percentage change. The data highlights significant increas", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anvs/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:52", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio (NYSE: ANVS) holders expand equity plan and set biennial say-on-pay", "summary": "Annovis Bio (NYSE: ANVS) stockholders approved all five proposals at their 2026 Annual Meeting. Key approvals include the election of five directors, ratification of Ernst & Young LLP as auditor, and an amendment to the 2019 Equity Incentive Plan to increase available shares. Sto", "url": "https://www.stocktitan.net/sec-filings/ANVS/8-k-annovis-bio-inc-reports-material-event-533241395040.html", "source_name": "Stock Titan", "published_at": "2026-06-17T20:39:52", "published_display": "17 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio Regains NYSE Listing Compliance", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNRkRDb0hmSHFMcUJPVVFZM1lrRl90aUdJcW10R0lIM1F2SjFoRVM3akRVem84TU0wYnlYZ3A5MWo4ODB4TFZ1dlY4bUZyWHFraXBUeEN3bVVaRXBaMlNBcGNWaGRDSmNtY0RaNXM0d213MXFORUF1WkVCWDBCZnhRTm1LTGpFUHBLMUhzUTM1cEx6YVJOQWZ2UnZEM29fbkNpeDM3dDZxV3ZTYzA1SjczdEdaaHY0QQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/annovis-announces-pricing-15-0-120000447.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T12:00:00+00:00", "published_display": "20 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Annovis prices $15M offer to fund Alzheimer\u2019s, Parkinson\u2019s studies", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxONV9mdm5OYm92dTU1cFUyckNwRWItU0tueDlVdG1sZXhWdHhWS09WWTN5VU93WEgtWDNRMC11dlFudUpod0d1QWRhNW9FRkg4ZTdINVRaYVV4OVRTeVJSVHpod1hqd01vcDVzaXphOTNxU3FuLWdwTFU5U0RLd0RlVUFsVHB2YW5CRjhqcDhyeTJxdjlpLU1GMV8wQy1Xc2ZqNUJPTmctME9VcW1abERlZjA4dnVqcnMxT042bG9Saw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio Launches Proposed Stock, Warrant Offering; Shares Fall", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/annovis-bio-launches-proposed-stock-210215149.html", "source_name": "MT Newswires", "published_at": "2026-05-19T21:02:15+00:00", "published_display": "19 May 2026 21:02", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPa2VyTzNQTE9GYTZJXzY1aHcyTVQ2OC1UbDI2cy1TWDZ2NUc2Q0s2SGczc0dsVTJUakdWRUFienVxQW01WGNGb3BHS082OE82OERNQV9ocm5kcTVTY3UwdmZ6WS1uVVpiV2hhT2U4MlYzRzdYMHFmX1FPNU9hTG95THpzOF9TQzJvczlOTEFTSzdqTFNEa1dKdEg3dVdzRk55S0FocXpIMFh5bUN6alE?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio announces public offering of stock and warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNc1FoSDRKOWlMNmtsd1hVdTRQSTd3NHdaZlAzVzFXa0dIdkJxMGoyZGxJYmpSR2pCbzFnb29Pbm9yQ0VYVnItLVFNTVg0aGMxb1Ytd2t3a1RvZ0VRenJwbEdwU3E2RnhYYU02MzNXQWVqc1Uza0VEWVBHeTV4ZzM5Y1diOFowcmd2TXVJTDhGOUpyYWRNSDJkOVJhd1hiTWJqWlFUbHJiaEZCRGVheFMyZVdHYS14cFU?oc=5", "source_name": "Investing.com", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio stock tumbles on public offering announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQVG5Fc3EzSTJRSWNyc3J3NmkycUdFcHlUblphN1l0cm5vTDJuVHhfMjROWUdIdjVLZmFPY0UybUo0dXpTdmRpWWtNNGlQbkE5d3dPYVRTb0MtV2VyY0hpYzZCTjdPZ2t6ZkIwcnRpQU9SdHNKdUV0VEdNMnJMMGZLWkpfR0VjQ1lqZzBueGZSdVVpOTE1ZzBzNl9WQlhFaUJvN0VVVlprMTRJVy1JWjAwdHYwdDB3NTNXaGRz?oc=5", "source_name": "Investing.com", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/annovis-provides-corporate-updates-reports-113000241.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T11:30:00+00:00", "published_display": "15 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Annovis drug showed cognition gains in early AD; 80% enrolled in Phase 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQOE1wRFZ2aUkwV3ZhLTF3MjdwNjlLSFVUMFVJa3JrWm53UjF0dW1fMWpxamkwQzg3d19HeE5QcXdJRjkyajJ2ODRuZ2JwWGE3R1gwX0F5SGp1Y05aSDBESTZ2cThWNkRKWlF5UFcyM0hxM1pTZ2FXTHRXVmU0bC1wbHByakZvQUlFZjN3TGdqbEgyS29VdzYwZU9rX3Njc1d6aXhYT0U5WTZnTjNqOFRyTVRiZHpkbnZSN0E?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A $10M cash boost puts Annovis on track for an Alzheimer\u2019s drug filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNUkJtN2p4R1p5Y2pyZVByY1dkeHlTWlFLNEVOTWNJM0J6QmduYjUtZC1wQjRRUkxTcFFkQjB3bE5KMTBqM2p5NG5PMmZITEhWNTl2cjk5NFROTVZsMlJibkJMcjhqQkY4dkFkWTE3UlFFcjJBdmVqQlcyd1hOQjF2Q3F2dDFSM2h5VldJSE9tMV9XU21rcnZXX3o5X1pqU3BxWGdFWUszdzlwZDVSWVdQalJnem1xazU3eUF3?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio prices $10M stock offering at $1.90 per share", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOcmZuZVBYa3I5TGpIaWtGZjdzTFJraGR0UU4xS3N1bGdhMGlSa0xqWXBySWZlUlJvNVZrcXdfYTlGYVFpYU8yQTdGYy04R1p5WEhfSTF3c3BPdUtfUGloclk0bXV1LXZFd1pzbHhfRzBxZ0JacXk0X2p2SW1La2pSam9jeFdvX3RhZWlpSzU1ZGx6aHVoTE5HdzlDdlVPWkZycW9YcUdVY3l6aGoxeUs0bA?oc=5", "source_name": "Investing.com", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Announces $10 Million Underwritten Offering Of Common Stock And Accompanying Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxNZUZXVkd6ZXJrR3M5ejhIbnFuYXRVcmlhbUNnNkw1Um94YjhWRmF2a1VkSE1TcVY2QVZ4VkRpSkcxTDFUU0RuVFJwR3U2aWRVVUZrbHQ3bzI0ZjVlM3FFX2VManlhdng2R0pxakY0czdYNW0wNFZBcWtid05EVC1NVGtfXzRxMExRczU1enhQRmlSVFg1TWJwWU4wZzlJWnN2LVpXZFQwZWEzclpMVkVWZU96QnhlUEVuNnFWTDRoV3drTS1iZjdwd1FqOTItUUtrdEpXeFRmYlllUldndEhkX0FUWDhFOVB1bHhuU0xDT29WZ0NI?oc=5", "source_name": "TradingView", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio, Inc. Secures Patent for Buntanetap in Prevention and Treatment of Neurological Injuries from Infectious Agents", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxPQU8xbWpKYTk2UE15QlFGcHpRck14MV9Wd01CRWdiOTRRdmN3ZmJoS3ppV2hKWHp6dWltclJDVHFNOHI5STdXN1JhTkFqclhtOWMxWmhDZUx0RnZwQ080S19YeW5FdmpkbzZaMnRpeG85TFYxWUQ1YWRBeVhiOUJGTnVSeGxia2pnX2FjUFk4TU1KY0tYSGdkVDNzZVpaOFM2b29RLXJIVmFnWGFfV1VPVnF1cThVMnV4TFI1Wnh0c3pQaWNyN1FIN09mcjNKYlpaOEdXTjc3VHdwUXoxXzhDMDI4ZFdGNjR1VUFDaUZzdw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANVS Stock Price and Chart \u2014 NYSE:ANVS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE4tNTFOcWJucGZyeG4ydkFFZlVCOUdEMTlXaFFGRkdxZzlMUlVFRWZRV25Xc2VEb0NtRGhxN1p2MG9SaUY3TVNGMzFyMmMxeEl6Z3RZRWxYa0F2dw?oc=5", "source_name": "TradingView", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Annovis Bio, Inc. Announces Business Updates and Financial Results for Fiscal Year 2025, Highlighting Pivotal Advances in Buntanetap Development for Neurodegenerative Diseases | ANVS Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgJBVV95cUxPd2gwd3dzRWhyemREM2tmMGMtcW9XOVVBNXZ3SWhfU19sYmJ6T201U2hRZVJlUElNbTFFZFRaWlVrOV9MejFNZEFCT2FLTGZlaTlxZzFET2hwRXlnalpTbl94dC1KT2R4NG1YdkxDa2tPZVh6QVpZUHB4RjBvTGx2b1FDWEJMOFdhTnFWczlCUFB3bXI4aVlIaW9iWWswTmM1NlJ3TmhmOFpwVmhFdkRMR2drZGVMUS1aVnNHamlUel9qdkg2Ql90N2Z0dUZKWlUtcmRJQXE5SXBadTFZajRxV0d2X3FSaU1yaDI3b0lldTQ2dFd0NV91V0tzZjNBc21rSzROQUpNS3dFX1NpS1lNYlE0aVNNcEtKYVpkQ3ZXRkdXOXNTTmljS3RDT3lGY1RfMEE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxON1Z2QjVYMDVpMHZIOGxDRTBRSnhVZUtRY0tiNXQ5WjZZQ2ROMmFQb3VtVHIwTXVtSEV4dWZ3NTdNY2hWN2xDemZLeFg5eFA5Nkt4eC1oVXZaUTh6dzZ3eWI0ODJRbXZtZTNGcmo4d01hWXpmTU55bEJMbVpsTHoyMmtTNk1fZFlYOGU0ZGxNUTlZQQ?oc=5", "source_name": "Market source", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio director Hoffman buys $159k in shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQZzBubzRHWThobUFPSXh5eTB3ZkdVbEt3MkxxaVhVZTVCOEh3bjB5U3ppT2o1d2JPMFV4dG5EZUhiQmlEdzF4TmtVTmdQRm1CV3F0RnhWOXVKelNkb28wZnRJajl0M2FuSzJPMVZyMlR0XzY5Y2VYb0ljTFlpbXF1NGRLU1hHejcybDFWTENyOUJZanQtNDVWakhrTjlUVWdjcHhHUGt2TEJlNXd3LVFCMnA0SQ?oc=5", "source_name": "Investing.com", "published_at": "2025-11-25T08:00:00+00:00", "published_display": "25 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAJBVV95cUxNUmJsWHd5YVZGQTZHMHJUV05SWWJsQ1ozeVo2UF9DemNmaXdKLTBoOU1hU0tRUTlYZG9CVkxMYzFacnV5TlAyVm1GNzRxbU5ueDUxZEtMNmF6cnVIOC1yM1NpNzV0X0dnYkZOQmFlV0xmaDJUWTd0dlhyaGNKTE1xM25IOW5EdlBUWVdBNlYxbmVUUDQ3cG1kM3R6dldaTUlUbW5waVc3TnhPcUtHRDdyQjNvOHBwMVFoUDlJUzFacW9uUnZkamJzbnJBU0gweXMwQlA3U2ZoeVJnQjBqYk5tcENGbzFCSmxXTlZUYjlKeHRCMklaQUxkZ1BjOTB6N2RiblRUbzQ5V3RXR1dsMGd0WWNGRzc?oc=5", "source_name": "Stocktwits", "published_at": "2025-11-18T08:00:00+00:00", "published_display": "18 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio (ANVS) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE52Q04xd3pGLXVTalU3Q0ZnTkF3eTVaeTBwSXhCb2NkZk1wR29uOFdLTTZiN3Y4Mnp5aUYyeEhSLWJ4NjdJVDJURERMcVR4S3lXUGIw?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:35:20+00:00", "published_display": "25 Apr 2025 01:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Annovis Reaches Full Enrollment in Phase 3 Buntanetap Trial, 850 Patients Enrolled", "summary": "Annovis Bio (ANVS) has fully enrolled 850 pTau217-confirmed early Alzheimer's disease patients in its pivotal Phase 3 buntanetap trial across 83 U.S. sites. The trial is randomized, placebo-controlled, and double-blind, with primary endpoints of ADAS-Cog13 and ADCS-iADL. Dual rea", "url": "https://www.tradingview.com/news/tradingview:b17ba2fb265f7:0-annovis-reaches-full-enrollment-in-phase-3-buntanetap-trial-850-patients-enrolled/", "source_name": "TradingView", "published_at": "2026-07-10T10:39:18", "published_display": "10 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio (NYSE: ANVS) completes enrollment in 850-patient Phase 3 Alzheimer\u2019s study", "summary": "Annovis Bio has announced the full enrollment of 850 patients in its pivotal Phase 3 trial for buntanetap, an investigational oral therapy for early Alzheimer's disease. The trial, exceeding original enrollment projections, will feature two separate data readouts: a 6-month sympt", "url": "https://www.stocktitan.net/sec-filings/ANVS/8-k-annovis-bio-inc-reports-material-event-00271f5e0b37.html", "source_name": "Stock Titan", "published_at": "2026-07-10T09:39:17", "published_display": "10 Jul 2026 09:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roth MKM Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $8", "summary": "Roth MKM has reiterated its Buy rating for Annovis Bio (ANVS.US) and maintained a target price of $8. This indicates the firm's continued confidence in the company's prospects.", "url": "https://www.moomoo.com/news/post/72737386/roth-mkm-maintains-annovis-bio-anvsus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-10T01:11:49", "published_display": "10 Jul 2026 01:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts\u2019 Top Healthcare Picks: Evolus (EOLS), Annovis Bio (ANVS)", "summary": "This article highlights two healthcare stocks, Evolus (EOLS) and Annovis Bio (ANVS), that analysts are bullish on. Evolus received a Buy rating and a $15.00 price target from Mizuho Securities, with a consensus of Strong Buy. Annovis Bio also maintained a Buy rating and an $8.00 ", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3211700/analysts-top-healthcare-picks-evolus-eols-annovis-bio-anvs/", "source_name": "The Globe and Mail", "published_at": "2026-07-09T20:14:16", "published_display": "09 Jul 2026 20:14", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Promotes Research Chief as Lead Drug Nears Key Trial", "summary": "Annovis Bio has promoted Cheng Fang to Chief Scientific Officer as the company advances its lead drug candidate, buntanetap, towards key clinical and regulatory milestones for Alzheimer's disease. Fang will oversee scientific strategy, clinical development, and regulatory interac", "url": "https://www.mychesco.com/a/news/business/executives/annovis-promotes-research-chief-as-lead-drug-nears-key-trial/", "source_name": "MyChesCo", "published_at": "2026-07-08T11:09:18", "published_display": "08 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The timeline for the key clinical trial data readout of Annovis Bio Inc. has been clarified.", "summary": "Annovis Bio Inc. has provided a clarified timeline for its key clinical trial data readouts. Results concerning symptom improvement efficacy are anticipated in the first quarter of 2027, while data evaluating the drug's impact on disease progression is expected in the first quart", "url": "https://www.bitget.com/amp/news/detail/12560605493681", "source_name": "Bitget", "published_at": "2026-07-07T13:11:18", "published_display": "07 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio completes enrollment in phase 3 Alzheimer\u2019s trial By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQZjlSdUtFbERrQWRhMno3R0l2alctWmFXN2NrbHBHU1ZZNDF4N2VNaFdOWGh6cEw5ZHlERy0tQncwbHJ0SGZ3X1h0Y19kelQ4UEpBU3dyZ0N5TVdYeWtIcy1UdTRLWmxtbTQ4XzMxd3lVaGYwcXZxWFJVdWc5T3RTNUF0ODI2VVRmTk5uV255anJYUWdkUFNlVlRzMUd4NEhfZkJOVGNUSnZ3amtGT3JZZGpSaGRva2hEdUdyRUVn?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T12:01:44+00:00", "published_display": "07 Jul 2026 12:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio Completes Patient Enrollment for Phase 3 Study of Buntanetap in Alzheimer's Disease", "summary": "Annovis Bio has successfully completed patient enrollment for its Phase 3 clinical trial evaluating buntanetap in patients with early Alzheimer's disease. The trial has fully enrolled 325 subjects across 50 sites, with topline results anticipated in the first quarter of 2027. Thi", "url": "https://www.moomoo.com/news/post/72582865/annovis-bio-completes-patient-enrollment-for-phase-3-study-of", "source_name": "Moomoo", "published_at": "2026-07-07T12:10:18", "published_display": "07 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio completes enrollment in phase 3 Alzheimer\u2019s trial", "summary": "Annovis Bio Inc. has successfully completed the enrollment of 850 patients in its pivotal Phase 3 clinical trial for buntanetap, a treatment for early Alzheimer\u2019s disease. The trial, exceeding its original enrollment target, will have two key data readouts: a 6-month analysis of ", "url": "https://www.investing.com/news/company-news/annovis-bio-completes-enrollment-in-phase-3-alzheimers-trial-93CH-4778792", "source_name": "Investing.com", "published_at": "2026-07-07T11:08:29", "published_display": "07 Jul 2026 11:08", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer\u2019s Disease", "summary": "Annovis Bio Inc. has fully enrolled its pivotal Phase 3 trial for buntanetap, an investigational oral therapy for early Alzheimer\u2019s disease, with 850 patients participating across 83 sites in the US. The trial aims to evaluate both symptomatic and disease-modifying effects, with ", "url": "https://www.globenewswire.com/news-release/2026/07/07/3323032/0/en/annovis-reaches-full-enrollment-in-pivotal-phase-3-trial-of-buntanetap-for-early-alzheimer-s-disease.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T11:00:03", "published_display": "07 Jul 2026 11:00", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis enrolls 850 patients in Phase 3 Alzheimer\u2019s study", "summary": "Annovis Bio (NYSE: ANVS) has fully enrolled 850 pTau217-positive patients in its pivotal Phase 3 trial of oral buntanetap for early Alzheimer\u2019s disease across 83 US sites. The dual-design study aims for 6-month symptomatic data by Q1 2027 and 18-month disease-modifying data by Q1", "url": "https://www.stocktitan.net/news/ANVS/annovis-reaches-full-enrollment-in-pivotal-phase-3-trial-of-g2h9kf5srbln.html", "source_name": "Stock Titan", "published_at": "2026-07-07T11:00:03", "published_display": "07 Jul 2026 11:00", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio Enrolls Over 850 Patients for Its Next Alzheimer's Disease Trial", "summary": "Annovis Bio announced the enrollment of over 850 patients for its upcoming Alzheimer's Disease trial. Sarah MacCallum and Cheng Fang from Annovis Bio discussed this development with Ashley Mastronardi on NYSE Live.", "url": "https://finance.yahoo.com/video/annovis-bio-enrolls-over-850-145156212.html", "source_name": "Market source", "published_at": "2026-07-07T10:51:00", "published_display": "07 Jul 2026 10:51", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The buntanetap program - Annovis Bio bets on neurodegeneration trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQdzU0bjRaUG5kdHc3V1Y2MDRLdFBES0Y5WXFDUmc1Uy1heWRUaGZ5eENTd2hKSFM0anBEN2dQY3RtRGZDTFdMRmMxWkROclc2VEpYdUxDa05KYUtDb25RYVpRcTBoWXhzUHZHMGtrb2d1WkpjZEpUU0JXaHhmUVZmckRGcU9qVXF1M1EyckI1ZWRaSHVwc1BZaGlDdW14ZUNsX0hDN1pkM2doODM1RnBZUXJpN0ZoOEw0ODl4dGhIekxOQnhS?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-04T22:38:45+00:00", "published_display": "04 Jul 2026 22:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer", "summary": "Annovis Bio, Inc. has promoted Dr. Cheng Fang to Chief Scientific Officer. Dr. Fang will lead the company's scientific strategy and research operations for its Alzheimer's and Parkinson's disease programs. Her promotion is critical as Annovis advances its lead drug candidate, bun", "url": "https://www.globenewswire.com/news-release/2026/07/01/3320540/0/en/annovis-appoints-cheng-fang-ph-d-as-chief-scientific-officer.html", "source_name": "GlobeNewswire", "published_at": "2026-07-01T21:09:44", "published_display": "01 Jul 2026 21:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio promotes Cheng Fang to chief scientific officer", "summary": "Annovis Bio Inc. has promoted Cheng Fang to Chief Scientific Officer. Fang will oversee the scientific strategy and research operations for the company's Alzheimer's and Parkinson's disease programs. This promotion comes as Annovis Bio advances its investigational oral therapy, b", "url": "https://www.investing.com/news/company-news/annovis-bio-promotes-cheng-fang-to-chief-scientific-officer-93CH-4770355", "source_name": "Investing.com", "published_at": "2026-07-01T12:41:06", "published_display": "01 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 62, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio Promotes Cheng Fang to Chief Scientific Officer Ahead of Phase 3 Milestones", "summary": "Annovis Bio Inc. has promoted Dr. Cheng Fang to Chief Scientific Officer, recognizing her expanded leadership role as the company approaches critical Phase 3 milestones for its lead drug candidate, buntanetap. Dr. Fang will now oversee scientific strategy and research operations ", "url": "https://www.citybiz.co/article/868362/annovis-bio-promotes-cheng-fang-to-chief-scientific-officer-ahead-of-phase-3-milestones/", "source_name": "citybiz", "published_at": "2026-07-01T12:40:18", "published_display": "01 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis elevates its R&D chief as Phase 3 Alzheimer\u2019s data nears", "summary": "Annovis Bio, Inc. has promoted Cheng Fang, Ph.D., to Chief Scientific Officer to lead scientific strategy and research operations for its Alzheimer\u2019s and Parkinson\u2019s programs. This promotion comes as the company approaches key milestones, including the release of top-line data fr", "url": "https://www.stocktitan.net/news/ANVS/annovis-appoints-cheng-fang-ph-d-as-chief-scientific-99hqqjrnidv9.html", "source_name": "Stock Titan", "published_at": "2026-07-01T11:40:18", "published_display": "01 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANVS - Annovis Bio Inc Latest SEC Filings", "summary": "This article provides detailed financial data and performance metrics for Annovis Bio Inc (ANVS), including its latest stock close, market capitalization, income, sales, and various valuation ratios. It also highlights insider and institutional ownership, short interest, and key ", "url": "https://finviz.com/stock?t=ANVS&ta=1&p=d&ty=lf&r=m1&page=6", "source_name": "Finviz", "published_at": "2026-06-30T20:40:18", "published_display": "30 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio, Inc.(NYSE: ANVS) added to Russell Microcap Index", "summary": "Annovis Bio, Inc. (NYSE: ANVS) has been added to the Russell Microcap Index. The company is a late-stage clinical drug platform company focused on neurodegenerative diseases like Alzheimer's and Parkinson's, developing product candidates such as Buntanetap, ANVS405, and ANVS301. ", "url": "https://www.marketscreener.com/news/annovis-bio-inc-nyse-anvs-added-to-russell-microcap-index-ce7f5fdeda80f02d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:40:27", "published_display": "29 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio, Inc.(NYSE: ANVS) added to Russell 3000E Index", "summary": "Annovis Bio, Inc. (NYSE: ANVS), a biotechnology company focused on neurodegenerative diseases, has been added to both the Russell 3000E Index and the Russell Microcap Index. This inclusion is a significant milestone, potentially increasing the company's visibility and attracting ", "url": "https://www.marketscreener.com/news/annovis-bio-inc-nyse-anvs-added-to-russell-3000e-index-ce7f5fdedd81f62c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T02:43:00", "published_display": "29 Jun 2026 02:43", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio, Inc.(NYSE: ANVS) added to Russell Microcap Growth Benchmark Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPSnNuSEp6YWdQWVI4XzdKUUVYTllpcVdsNUF0Nl9kUTBFeW1sY2pIUWtCWUZkZTIzTER3dkhXNng4UlkyM3gyeDN3RFZGMF8xOWxYZDlMMkRWNWZHMGdxUWZ4THpINklqWU1nS0UzSU9jRzRTYlpnVFp5eW1MM1RpWHdiT3RSd2s1M1drMVNQUm1aQVJYMHRHZHFtRTNNUUk5MWh2LUs4SWNwaW9zaEU1VlJudmRsUnVpY2lXcS15M0hsNnEzLWc?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T22:00:00+00:00", "published_display": "28 Jun 2026 22:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio Inc Actuals & Estimates (TRADEGATE:07X)", "summary": "This article provides an overview of Annovis Bio Inc (TRADEGATE:07X) financials and analyst estimates. It details the company's past earnings and revenue, future earnings forecasts, and historical stock performance including its all-time high and low prices. The article also conf", "url": "https://www.tradingview.com/symbols/TRADEGATE-07X/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T08:41:06", "published_display": "27 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio | DEFA14A: Others", "summary": "This article is a DEFA14A filing by Annovis Bio. DEFA14A filings are definitive additional soliciting materials filed with the SEC. The content of this specific filing is \"Document\".", "url": "https://www.moomoo.com/news/notice/307206668/annovis-bio-defa14a-others", "source_name": "Moomoo", "published_at": "2026-06-27T07:10:44", "published_display": "27 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio Inc Actuals & Estimates (FWB:07X)", "summary": "This article provides financial actuals and estimates for Annovis Bio Inc (FWB:07X), including analyst price targets, historical stock prices, and upcoming earnings dates. It highlights that the company's stock ticker on the FWB exchange is 07X and details past earnings performan", "url": "https://www.tradingview.com/symbols/FWB-07X/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:16", "published_display": "26 Jun 2026 07:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Annovis Bio, Inc. \u2013 NYSE:ANVS", "summary": "The document displays financial information for Annovis Bio, Inc. (NYSE: ANVS), specifically focusing on its forward price-to-sales ratio. It indicates that the market was closed with no trades at the time of viewing. The content primarily comes from TradingView, with market and ", "url": "https://www.tradingview.com/symbols/NYSE-ANVS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T06:11:23", "published_display": "26 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Annovis Bio, Inc. \u2013 NYSE:ANVS", "summary": "This article provides financial information for Annovis Bio, Inc. (NYSE:ANVS), specifically focusing on its enterprise value to revenue forward ratio. The content is primarily a data point or financial metric display from TradingView, which indicates the company's valuation relat", "url": "https://www.tradingview.com/symbols/NYSE-ANVS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T15:41:59", "published_display": "25 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio Inc (ANVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Annovis Bio Inc (ANVS), detailing its support, resistance, indicators, and moving averages. According to the analysis, various indicators like MACD and TRIX show sell signals, along with all moving averages from MA5 to MA200. The over", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anvs/technical", "source_name": "TradingKey", "published_at": "2026-06-21T17:10:34", "published_display": "21 Jun 2026 17:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio Shareholders Approve Governance and Compensation Changes", "summary": "Annovis Bio shareholders approved significant governance and compensation changes at their 2026 Annual Meeting, including the election of all five director nominees and the ratification of Ernst & Young LLP as auditor. Investors also approved an amendment to the 2019 Equity Incen", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ANVS-N/pressreleases/2547111/annovis-bio-shareholders-approve-governance-and-compensation-changes/", "source_name": "The Globe and Mail", "published_at": "2026-06-19T15:38:46", "published_display": "19 Jun 2026 15:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Annovis\u2019 buntanetap pill is drawing fresh attention in Alzheimer\u2019s race", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQcHVzUm5CWjVrYWNWSjY5a19FWV9qLUUwMjN6N2VuOEJ5bXNsUXpCTnJlQkZlTm9OS0M5a2M5NUJkaHFuYnljS1hkWTJ3MW5ZcXo4aXpMdmpKa2ptYm5SajRta2thWDE2a013Vk5oX3ptbHBONW5vX2V0b2VPMUthS2hoalg4elNoZHBIVEZCRUd5RzN5NGtRbDVfOEVaZWotV0ZqSVhxWF9CS3BRVnc2VVVrclBvdk51VUZuRUhOT25Ca29YdjIw?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio shareholders approve all proposals at annual meeting", "summary": "Annovis Bio, Inc. shareholders approved all proposals at their 2026 Annual Meeting. Key approvals included the re-election of five directors, the ratification of Ernst & Young LLP as auditors, and an amendment to the 2019 Equity Incentive Plan to increase issuable shares. Shareho", "url": "https://m.investing.com/news/sec-filings/annovis-bio-shareholders-approve-all-proposals-at-annual-meeting-93CH-4748658?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-17T22:39:52", "published_display": "17 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio Inc (ANVS) Institutional Confidence", "summary": "This article from TradingKey provides an overview of Annovis Bio Inc (ANVS) with a specific focus on \"Institutional Confidence.\" It lists key institutional shareholders and their recent activity, including shares held and percentage change. The data highlights significant increas", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anvs/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:52", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio (NYSE: ANVS) holders expand equity plan and set biennial say-on-pay", "summary": "Annovis Bio (NYSE: ANVS) stockholders approved all five proposals at their 2026 Annual Meeting. Key approvals include the election of five directors, ratification of Ernst & Young LLP as auditor, and an amendment to the 2019 Equity Incentive Plan to increase available shares. Sto", "url": "https://www.stocktitan.net/sec-filings/ANVS/8-k-annovis-bio-inc-reports-material-event-533241395040.html", "source_name": "Stock Titan", "published_at": "2026-06-17T20:39:52", "published_display": "17 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio Regains NYSE Listing Compliance", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNRkRDb0hmSHFMcUJPVVFZM1lrRl90aUdJcW10R0lIM1F2SjFoRVM3akRVem84TU0wYnlYZ3A5MWo4ODB4TFZ1dlY4bUZyWHFraXBUeEN3bVVaRXBaMlNBcGNWaGRDSmNtY0RaNXM0d213MXFORUF1WkVCWDBCZnhRTm1LTGpFUHBLMUhzUTM1cEx6YVJOQWZ2UnZEM29fbkNpeDM3dDZxV3ZTYzA1SjczdEdaaHY0QQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/annovis-announces-pricing-15-0-120000447.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T12:00:00+00:00", "published_display": "20 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Annovis prices $15M offer to fund Alzheimer\u2019s, Parkinson\u2019s studies", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxONV9mdm5OYm92dTU1cFUyckNwRWItU0tueDlVdG1sZXhWdHhWS09WWTN5VU93WEgtWDNRMC11dlFudUpod0d1QWRhNW9FRkg4ZTdINVRaYVV4OVRTeVJSVHpod1hqd01vcDVzaXphOTNxU3FuLWdwTFU5U0RLd0RlVUFsVHB2YW5CRjhqcDhyeTJxdjlpLU1GMV8wQy1Xc2ZqNUJPTmctME9VcW1abERlZjA4dnVqcnMxT042bG9Saw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio Launches Proposed Stock, Warrant Offering; Shares Fall", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/annovis-bio-launches-proposed-stock-210215149.html", "source_name": "MT Newswires", "published_at": "2026-05-19T21:02:15+00:00", "published_display": "19 May 2026 21:02", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPa2VyTzNQTE9GYTZJXzY1aHcyTVQ2OC1UbDI2cy1TWDZ2NUc2Q0s2SGczc0dsVTJUakdWRUFienVxQW01WGNGb3BHS082OE82OERNQV9ocm5kcTVTY3UwdmZ6WS1uVVpiV2hhT2U4MlYzRzdYMHFmX1FPNU9hTG95THpzOF9TQzJvczlOTEFTSzdqTFNEa1dKdEg3dVdzRk55S0FocXpIMFh5bUN6alE?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio announces public offering of stock and warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNc1FoSDRKOWlMNmtsd1hVdTRQSTd3NHdaZlAzVzFXa0dIdkJxMGoyZGxJYmpSR2pCbzFnb29Pbm9yQ0VYVnItLVFNTVg0aGMxb1Ytd2t3a1RvZ0VRenJwbEdwU3E2RnhYYU02MzNXQWVqc1Uza0VEWVBHeTV4ZzM5Y1diOFowcmd2TXVJTDhGOUpyYWRNSDJkOVJhd1hiTWJqWlFUbHJiaEZCRGVheFMyZVdHYS14cFU?oc=5", "source_name": "Investing.com", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio stock tumbles on public offering announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQVG5Fc3EzSTJRSWNyc3J3NmkycUdFcHlUblphN1l0cm5vTDJuVHhfMjROWUdIdjVLZmFPY0UybUo0dXpTdmRpWWtNNGlQbkE5d3dPYVRTb0MtV2VyY0hpYzZCTjdPZ2t6ZkIwcnRpQU9SdHNKdUV0VEdNMnJMMGZLWkpfR0VjQ1lqZzBueGZSdVVpOTE1ZzBzNl9WQlhFaUJvN0VVVlprMTRJVy1JWjAwdHYwdDB3NTNXaGRz?oc=5", "source_name": "Investing.com", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/annovis-provides-corporate-updates-reports-113000241.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T11:30:00+00:00", "published_display": "15 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis drug showed cognition gains in early AD; 80% enrolled in Phase 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQOE1wRFZ2aUkwV3ZhLTF3MjdwNjlLSFVUMFVJa3JrWm53UjF0dW1fMWpxamkwQzg3d19HeE5QcXdJRjkyajJ2ODRuZ2JwWGE3R1gwX0F5SGp1Y05aSDBESTZ2cThWNkRKWlF5UFcyM0hxM1pTZ2FXTHRXVmU0bC1wbHByakZvQUlFZjN3TGdqbEgyS29VdzYwZU9rX3Njc1d6aXhYT0U5WTZnTjNqOFRyTVRiZHpkbnZSN0E?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A $10M cash boost puts Annovis on track for an Alzheimer\u2019s drug filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNUkJtN2p4R1p5Y2pyZVByY1dkeHlTWlFLNEVOTWNJM0J6QmduYjUtZC1wQjRRUkxTcFFkQjB3bE5KMTBqM2p5NG5PMmZITEhWNTl2cjk5NFROTVZsMlJibkJMcjhqQkY4dkFkWTE3UlFFcjJBdmVqQlcyd1hOQjF2Q3F2dDFSM2h5VldJSE9tMV9XU21rcnZXX3o5X1pqU3BxWGdFWUszdzlwZDVSWVdQalJnem1xazU3eUF3?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio prices $10M stock offering at $1.90 per share", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOcmZuZVBYa3I5TGpIaWtGZjdzTFJraGR0UU4xS3N1bGdhMGlSa0xqWXBySWZlUlJvNVZrcXdfYTlGYVFpYU8yQTdGYy04R1p5WEhfSTF3c3BPdUtfUGloclk0bXV1LXZFd1pzbHhfRzBxZ0JacXk0X2p2SW1La2pSam9jeFdvX3RhZWlpSzU1ZGx6aHVoTE5HdzlDdlVPWkZycW9YcUdVY3l6aGoxeUs0bA?oc=5", "source_name": "Investing.com", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Announces $10 Million Underwritten Offering Of Common Stock And Accompanying Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxNZUZXVkd6ZXJrR3M5ejhIbnFuYXRVcmlhbUNnNkw1Um94YjhWRmF2a1VkSE1TcVY2QVZ4VkRpSkcxTDFUU0RuVFJwR3U2aWRVVUZrbHQ3bzI0ZjVlM3FFX2VManlhdng2R0pxakY0czdYNW0wNFZBcWtid05EVC1NVGtfXzRxMExRczU1enhQRmlSVFg1TWJwWU4wZzlJWnN2LVpXZFQwZWEzclpMVkVWZU96QnhlUEVuNnFWTDRoV3drTS1iZjdwd1FqOTItUUtrdEpXeFRmYlllUldndEhkX0FUWDhFOVB1bHhuU0xDT29WZ0NI?oc=5", "source_name": "TradingView", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio, Inc. Secures Patent for Buntanetap in Prevention and Treatment of Neurological Injuries from Infectious Agents", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxPQU8xbWpKYTk2UE15QlFGcHpRck14MV9Wd01CRWdiOTRRdmN3ZmJoS3ppV2hKWHp6dWltclJDVHFNOHI5STdXN1JhTkFqclhtOWMxWmhDZUx0RnZwQ080S19YeW5FdmpkbzZaMnRpeG85TFYxWUQ1YWRBeVhiOUJGTnVSeGxia2pnX2FjUFk4TU1KY0tYSGdkVDNzZVpaOFM2b29RLXJIVmFnWGFfV1VPVnF1cThVMnV4TFI1Wnh0c3pQaWNyN1FIN09mcjNKYlpaOEdXTjc3VHdwUXoxXzhDMDI4ZFdGNjR1VUFDaUZzdw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANVS Stock Price and Chart \u2014 NYSE:ANVS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE4tNTFOcWJucGZyeG4ydkFFZlVCOUdEMTlXaFFGRkdxZzlMUlVFRWZRV25Xc2VEb0NtRGhxN1p2MG9SaUY3TVNGMzFyMmMxeEl6Z3RZRWxYa0F2dw?oc=5", "source_name": "TradingView", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio, Inc. Announces Business Updates and Financial Results for Fiscal Year 2025, Highlighting Pivotal Advances in Buntanetap Development for Neurodegenerative Diseases | ANVS Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgJBVV95cUxPd2gwd3dzRWhyemREM2tmMGMtcW9XOVVBNXZ3SWhfU19sYmJ6T201U2hRZVJlUElNbTFFZFRaWlVrOV9MejFNZEFCT2FLTGZlaTlxZzFET2hwRXlnalpTbl94dC1KT2R4NG1YdkxDa2tPZVh6QVpZUHB4RjBvTGx2b1FDWEJMOFdhTnFWczlCUFB3bXI4aVlIaW9iWWswTmM1NlJ3TmhmOFpwVmhFdkRMR2drZGVMUS1aVnNHamlUel9qdkg2Ql90N2Z0dUZKWlUtcmRJQXE5SXBadTFZajRxV0d2X3FSaU1yaDI3b0lldTQ2dFd0NV91V0tzZjNBc21rSzROQUpNS3dFX1NpS1lNYlE0aVNNcEtKYVpkQ3ZXRkdXOXNTTmljS3RDT3lGY1RfMEE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxON1Z2QjVYMDVpMHZIOGxDRTBRSnhVZUtRY0tiNXQ5WjZZQ2ROMmFQb3VtVHIwTXVtSEV4dWZ3NTdNY2hWN2xDemZLeFg5eFA5Nkt4eC1oVXZaUTh6dzZ3eWI0ODJRbXZtZTNGcmo4d01hWXpmTU55bEJMbVpsTHoyMmtTNk1fZFlYOGU0ZGxNUTlZQQ?oc=5", "source_name": "Market source", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio director Hoffman buys $159k in shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQZzBubzRHWThobUFPSXh5eTB3ZkdVbEt3MkxxaVhVZTVCOEh3bjB5U3ppT2o1d2JPMFV4dG5EZUhiQmlEdzF4TmtVTmdQRm1CV3F0RnhWOXVKelNkb28wZnRJajl0M2FuSzJPMVZyMlR0XzY5Y2VYb0ljTFlpbXF1NGRLU1hHejcybDFWTENyOUJZanQtNDVWakhrTjlUVWdjcHhHUGt2TEJlNXd3LVFCMnA0SQ?oc=5", "source_name": "Investing.com", "published_at": "2025-11-25T08:00:00+00:00", "published_display": "25 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAJBVV95cUxNUmJsWHd5YVZGQTZHMHJUV05SWWJsQ1ozeVo2UF9DemNmaXdKLTBoOU1hU0tRUTlYZG9CVkxMYzFacnV5TlAyVm1GNzRxbU5ueDUxZEtMNmF6cnVIOC1yM1NpNzV0X0dnYkZOQmFlV0xmaDJUWTd0dlhyaGNKTE1xM25IOW5EdlBUWVdBNlYxbmVUUDQ3cG1kM3R6dldaTUlUbW5waVc3TnhPcUtHRDdyQjNvOHBwMVFoUDlJUzFacW9uUnZkamJzbnJBU0gweXMwQlA3U2ZoeVJnQjBqYk5tcENGbzFCSmxXTlZUYjlKeHRCMklaQUxkZ1BjOTB6N2RiblRUbzQ5V3RXR1dsMGd0WWNGRzc?oc=5", "source_name": "Stocktwits", "published_at": "2025-11-18T08:00:00+00:00", "published_display": "18 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annovis Bio (ANVS) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE52Q04xd3pGLXVTalU3Q0ZnTkF3eTVaeTBwSXhCb2NkZk1wR29uOFdLTTZiN3Y4Mnp5aUYyeEhSLWJ4NjdJVDJURERMcVR4S3lXUGIw?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:35:20+00:00", "published_display": "25 Apr 2025 01:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 102, "total_relevant": 63, "sentiment_summary": {"positive": 21, "negative": 4, "neutral": 38, "score": 57, "total": 63, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 19.8, "count": 36}, {"event": "earnings", "label": "Earnings", "weight": 8.66, "count": 18}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 21, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 1.86, "latest_week": "2026-07-10", "one_week_move": -3.6, "four_week_move": 4.5, "twelve_week_move": -0.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.121599, "market_dynamics_buy_signal": false, "relative_strength": -33.774009, "fair_value_gap": -68.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.4567, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.6% over one week, +4.5% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 67, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "TradingView", "count": 8}, {"label": "Stock Titan", "count": 8}, {"label": "Investing.com", "count": 7}, {"label": "GlobeNewswire", "count": 5}, {"label": "Moomoo", "count": 3}, {"label": "The Globe and Mail", "count": 2}, {"label": "ad-hoc-news.de", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Earnings", "count": 18}, {"label": "Regulatory and legal", "count": 4}, {"label": "Analyst action", "count": 4}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-3.6% over one week, +4.5% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Annovis Reaches Full Enrollment in Phase 3 Buntanetap Trial, 850 Patients Enrolled"}], "updated_at": "2026-07-17T18:13:59.335420+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}